The Medicines Company invests $8m in GeNO, which is researching nitric oxide treatments.
US-based medical technology developer GeNO raised $8m yesterday in a round funded by pharmaceutical corporation The Medicines Company (MDCO). According to the initial announcement, on 5th December, MDCO will gain an exclusive licensing option for GeNO’s nitric oxide (NO) delivery products in certain regions as well as a minority equity stake in the firm.
GeNO previously raised about $3m in two separate funding rounds, in 2006 and 2009 respectively.
GeNO’s nitric oxide therapy is primarily being developed to treat symptoms…
